Raphael Pharmaceutical Inc.

Raphael Pharmaceutical Inc. is a pharmaceutical drug research and development company. Incorporated in Nevada in May 2007 as Easy Energy, Inc., it changed its name on May 19, 2021, following a share exchange on May 14, 2021, with Raphael Pharmaceutical Ltd. (Raphael Israel), an Israeli company incorporated in 2019. Raphael Israel's shareholders now hold 90% of the company's issued and outstanding share capital, while Easy Energy, Inc.'s original shareholders hold 10%. The company adopted Raphael Israel's business plan, as Easy Energy did not have ongoing business or operations before the share exchange. Raphael Pharmaceutical Inc. focuses on discovering and clinically developing drug therapies based on cannabinoids, specifically cannabidiol (CBD) oil. The company plans to use oil derived from CBD strains with less than 0.3% Tetrahydrocannabinol (THC). Its lead product candidate is for the treatment of rheumatoid arthritis (RA). In December 2024, the company completed a proof-of-concept clinical study for this RA treatment in the U.S. The company also aims to develop a novel treatment for asthma. Studies using human-derived immune cells and mouse models have been conducted at Rambam Health Care Campus, Rambam Med-Tech Ltd., to advance understanding of both COVID-19 and RA products, which also contributes to understanding asthma due to symptom similarities.